Land: Australien
Sprache: Englisch
Quelle: APVMA (Australian Pesticides and Veterinary Medicines Authority)
HALOFUGINONE BASE AS THE LACTATE
INTERVET AUSTRALIA PTY LIMITED
halofuginone(0.5g/L)
ORAL SOLUTION/SUSPENSION
HALOFUGINONE BASE AS THE LACTATE ANTIPROTOZOAL Active 0.5 g/L
490mL; 980mL
VM - Veterinary Medicine
INTERVET AUSTRALIA
CALF | BEEF CALF | BOVINE | CALF - PODDY | CALF - PREWEANING | CALF - SUCKER | DAIRY CALF | NEONATAL CALF
PARASITICIDES
DIARRHEOA CAUSE CRYPTOSPORIDIUM PARVUM | CRYPTOSPORIDIUM PARVUM
Poison schedule: 4; Withholding period: MEAT AND OFFAL: DO NOT USE LESS THAN 13 DAYS BEFORE SLAUGHTER FOR HUMAN CONSUMP TION. DO NOT SLAUGHTER FOR EXPORT FOR 1 7 DAYS AFTER LAST TREATMENT. THE ESI ON THIS LABEL WAS CORRECT AT THE TIME OF L ABEL APPROVAL. BEFORE USING THIS PRODUCT CONFIRM THE CURRENT ESI FROM INTERVET A USTRALIA ON 1800 033 461 (AUSTRALIAN CAL LERS ONLY) OR VIA THE APVMA WEBSITE AT: www.apvma.gov/residues/ESI.shtml; Host/pest details: CALF: [DIARRHEOA CAUSE CRYPTOSPORIDIUM PARVUM]; Poison schedule: 4; Withholding period: WHP: MEAT AND OFFAL: DO NOT USE LESS THAN 13 DAYS BEFORE SLAUGHTER FOR HUMAN CONSUMPTION. ESI: DO NOT SLAUGHTER FO R EXPORT FOR 17 DAYS AFTER LAST TREATME NT. THE ESI ON THIS LABEL WAS CORRECT A T THE TIME OF LABEL APPROVAL. BEFORE US ING THIS PRODUCT CONFIRM THE CURRENT E SI FROM INTERVET AUSTRALIA ON 1800 033 461 (AUSTRALIAN CALLERS ONLY) OR VIA TH E APVMA WEBSITE AT: www.APVMA.gov/resi dues/ESI.shtml; Host/pest details: CALF: [DIARRHEOA CAUSE CRYPTOSPORIDIUM PARVUM]; Poison schedule: 4; Withholding period: ; Host/pest details: CALF: [DIARRHEOA CAUSE CRYPTOSPORIDIUM PARVUM]; An aid in the control and prevention of diarrhoea caused by Cryptosporidium parvum in calves.DO NOT expose calves to a second period of treatment. DO NOT treat calves over 21 days of age. DO NOT use where diarrhoea has been established for more than 24 hours and in weak animals. OTHER PRECAUTIONS, SPECIAL PRECAUTIONS, etc: SEE LABEL.
Registered
2023-07-01
HALOCUR ORAL SOLUTION FOR TREATMENT OF CALVES 57163/129146 Product Name: APVMA Approval No: Label Name: HALOCUR ORAL SOLUTION FOR TREATMENT OF CALVES Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY READ SAFETY DIRECTIONS BEFORE OPENING OR USING Constituent Statements: 0.5 g/L HALOFUGINONE BASE (as the lactate) Claims: An aid in the control and prevention of diarrhoea caused by Cryptosporidium parvum in calves. INDICATIONS In new born calves: - For the prevention of diarrhoea due to a confirmed diagnosis of Cryptosporidium parvum, on properties with a history of cryptosporidiosis, treatment should be commenced within 24 - 48 hours of birth. - For the control of diarrhoea caused by Cryptosporidium parvum, treatment should be commenced within 24 hours after onset of diarrhoea. Net Contents: 490 mL 980 mL Directions for Use: Restraints: DO NOT expose calves to a second period of treatment. DO NOT treat calves over 21 days of age. Contraindications: Precautions: For ORAL administration only - DO NOT inject. RLP APPROVED Do not administer to calves that have an empty stomach. Do not use where diarrhoea has been established for more than 24 hours and in weak animals. For treatment of anorexic calves, the product should be administered in half a litre of electrolyte solution. Calves should receive sufficient colostrum according to standard calf rearing management practices. Halocur should be used where Cryptosporidium parvum has been confirmed as a cause of diarrhoea. There are several diagnostic methods available to confirm the presence of C. parvum including laboratory examination of faecal samples for oocysts as well as ELISA technologies. Laboratory examination must be used to rule out other infectious agents as contributing factors. Special precautions: As symptoms of toxicity may occur at 2 times the therapeutic dose, it is important to strictly adhere to the recommended dose rate. Symptoms of toxicity include diarrhoea, visible blood in faeces, decline in milk co Lesen Sie das vollständige Dokument
PRODUCT NAME: HALOCUR 0.5MG/ML ORAL SOLUTION FOR TREATMENT OF CALVES MATERIAL SAFETY DATA SHEET PAGE: 1 OF 5 THIS REVISION ISSUED: FEBRUARY, 2007 MATERIAL SAFETY DATA SHEET Issued by: Intervet Australia Pty Limited Phone: 1 800 033 461 (Business Hours) Poisons Information Centre: 13 11 26 from anywhere in Australia, (0800 764 766 in New Zealand) SUBSTANCE: Halofuginone is an quinazolinone alkaloid. TRADE NAME: HALOCUR 0.5MG/ML ORAL SOLUTION FOR TREATMENT OF CALVES RECOMMENDED USE: An aid in the control and prevention of diarrhoea caused by _Cryptospiridum parvum _in calves. APVMA NO: 57163 CREATION DATE: February, 2007 THIS REVISION DATE: February, 2007 STATEMENT OF HAZARDOUS NATURE: THIS PRODUCT IS CLASSIFIED AS: N, Dangerous to the environment. Not classified as hazardous according to the criteria of ASCC. Not a Dangerous Good according to the Australian Dangerous Goods (ADG) Code. RISK PHRASES: R50/53. Very toxic to aquatic organisms, may cause long-term adverse effects to the aquatic environment. SAFETY PHRASES: S20, S23, S25, S60, S61. When using, do not eat or drink. Do not breathe mists. Avoid contact with eyes. This material and its container must be disposed of as hazardous waste. Avoid release to the environment. Refer to special instructions/Safety Data Sheets. SUSDP CLASSIFICATION: S4 ADG CLASSIFICATION: None allocated. Not a Dangerous Good under the ADG Code. UN NUMBER: None allocated PHYSICAL DESCRIPTION & COLOUR: Clear yellowish liquid. ODOUR: No data. MAJOR HEALTH HAZARDS: no significant risk factors have been found for this product. INHALATION: SHORT TERM EXPOSURE: Available data indicates that this product is not harmful. However product may be mildly irritating, although unlikely to cause anything more than mild transient discomfort. LONG TERM EXPOSURE: No data for health effects associated with long term inhalation. SKIN CONTACT: SHORT TERM EXPOSURE: Available data indicates that this product is not harmful. It should present no hazards in normal use. However product may be mildly irritating, Lesen Sie das vollständige Dokument